相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。ALK Inhibitor Response in Melanomas Expressing EML4-ALK Fusions and Alternate ALK Isoforms
Kasey L. Couts et al.
MOLECULAR CANCER THERAPEUTICS (2018)
MEK drives BRAF activation through allosteric control of KSR proteins
Hugo Lavoie et al.
NATURE (2018)
Identification of NTRK3 Fusions in Childhood Melanocytic Neoplasms
Lu Wang et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2017)
Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib)
Ursula A. Germann et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition
H. S. Kim et al.
ONCOGENE (2017)
Kinase gene fusions in defined subsets of melanoma
Jacqueline Turner et al.
PIGMENT CELL & MELANOMA RESEARCH (2017)
Engineering and Functional Characterization of Fusion Genes Identifies Novel Oncogenic Drivers of Cancer
Hengyu Lu et al.
CANCER RESEARCH (2017)
The distribution of BRAF gene fusions in solid tumors and response to targeted therapy
Jeffrey S. Ross et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
Feedback activation of neurofibromin terminates growth factor-induced Ras activation
Anne Hennig et al.
CELL COMMUNICATION AND SIGNALING (2016)
BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy
Samuel J. Klempner et al.
CANCER DISCOVERY (2016)
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Stacey Bagby et al.
JOVE-JOURNAL OF VISUALIZED EXPERIMENTS (2016)
Structural and Thermodynamic Properties of Septin 3 Investigated by Small-Angle X-Ray Scattering
Maria Grazia Ortore et al.
BIOPHYSICAL JOURNAL (2015)
The role of BRAF mutations in primary melanoma growth rate and survival
V. J. Mar et al.
BRITISH JOURNAL OF DERMATOLOGY (2015)
Colorectal Cancer Heterogeneity and Targeted Therapy: A Case for Molecular Disease Subtypes
Janneke F. Linnekamp et al.
CANCER RESEARCH (2015)
Pathogenetic Implications of BRAF Mutation Distribution in Stage IV Melanoma Patients
Mirjam Baiter et al.
DERMATOLOGY (2015)
Targeted Therapy for Patients with BRAF-Mutant Lung Cancer Results from the European EURAF Cohort
Oliver Gautschi et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion
Alexander M. Menzies et al.
PIGMENT CELL & MELANOMA RESEARCH (2015)
Clonal status of actionable driver events and the timing of mutational processes in cancer evolution
Nicholas McGranahan et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Sustained proliferation in cancer: Mechanisms and novel therapeutic targets
Mark A. Feitelson et al.
SEMINARS IN CANCER BIOLOGY (2015)
Tissue invasion and metastasis: Molecular, biological and clinical perspectives
W. G. Jiang et al.
SEMINARS IN CANCER BIOLOGY (2015)
An Efficient Method for Identifying Gene Fusions by Targeted RNA Sequencing from Fresh Frozen and FFPE Samples
Jonathan A. Scolnick et al.
PLOS ONE (2015)
BRAF Fusions Define a Distinct Molecular Subset of Melanomas with Potential Sensitivity to MEK Inhibition
Katherine E. Hutchinson et al.
CLINICAL CANCER RESEARCH (2013)
Cancer immunotherapies, their safety and toxicity
Gheath Alatrash et al.
EXPERT OPINION ON DRUG SAFETY (2013)
Oncogenic B-Raf signaling in melanoma cells controls a network of microRNAs with combinatorial functions
K. L. Couts et al.
ONCOGENE (2013)
Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy
Thomas Botton et al.
PIGMENT CELL & MELANOMA RESEARCH (2013)
Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas
Angela J. Sievert et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Concurrent MEK2 Mutation and BRAF Amplification Confer Resistance to BRAF and MEK Inhibitors in Melanoma
Jessie Villanueva et al.
CELL REPORTS (2013)
Transmembrane helix dimerization: Beyond the search for sequence motifs
Edwin Li et al.
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES (2012)
RET, ROS1 and ALK fusions in lung cancer
Kengo Takeuchi et al.
NATURE MEDICINE (2012)
NIH Image to ImageJ: 25 years of image analysis
Caroline A. Schneider et al.
NATURE METHODS (2012)
Patient-derived tumour xenografts as models for oncology drug development
John J. Tentler et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
Poulikos I. Poulikakos et al.
NATURE (2011)
Regulation of RAF Activity by 14-3-3 Proteins RAF KINASES ASSOCIATE FUNCTIONALLY WITH BOTH HOMO- AND HETERODIMERIC FORMS OF 14-3-3 PROTEINS
Andreas Fischer et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Aberrant BRAF splicing as an alternative mechanism for oncogenic B-Raf activation in thyroid carcinoma
Essa Y. Baitei et al.
JOURNAL OF PATHOLOGY (2009)
Functional analysis of the regulatory requirements of B-Raf and the B-RafV600E oncoprotein
T. Brummer et al.
ONCOGENE (2006)
分享论文
